Lifetime Cost Effectiveness of Phenylketonuria Screening Na-tional Program in Iran
Background: Phenylketonuria (PKU) is an autosomal recessive disorder that screening and timely control of this disorder can prevent the adverse effects. Regarding the high prevalence of PKU in Iran, the PKU screening program was started in Iran in 2006. This study was conducted to determine the cos...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Tehran University of Medical Sciences
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d329c8e167cc4ad4ba25f7b96aa5bc6a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d329c8e167cc4ad4ba25f7b96aa5bc6a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d329c8e167cc4ad4ba25f7b96aa5bc6a2021-12-02T19:21:11ZLifetime Cost Effectiveness of Phenylketonuria Screening Na-tional Program in Iran10.18502/ijph.v50i10.75122251-60852251-6093https://doaj.org/article/d329c8e167cc4ad4ba25f7b96aa5bc6a2021-10-01T00:00:00Zhttps://ijph.tums.ac.ir/index.php/ijph/article/view/18078https://doaj.org/toc/2251-6085https://doaj.org/toc/2251-6093 Background: Phenylketonuria (PKU) is an autosomal recessive disorder that screening and timely control of this disorder can prevent the adverse effects. Regarding the high prevalence of PKU in Iran, the PKU screening program was started in Iran in 2006. This study was conducted to determine the cost-effectiveness of PKU screening in Iran. Methods: An economic evaluation was performed among screened and treated individuals compared to no screening in 2013. The study population included 1356132 newborns that screened for PKU diagnosis. Lifetime costs, quality-adjusted life year (QALY) gains and incremental cost-effectiveness ratio (ICER) were calculated from the perspective of government. A discount rate of 3% was considered for both QALYs and costs. A one-way sensitivity analysis was used for assessing the robustness of the results. Results: The discounted lifetime cost of intervention and non-intervention were $59528953.8 and $85295501.6 respectively. Therefore, the total estimated cost saving was $25766547.84. PKU screening produces an ICER of $1844420 per QALY gained. Conclusion: Screening and early treatment for PKU is highly cost-effective. Therefore, the screening can improve quality of life of the patients and increase financial saving in health system. Alireza HeidariMohammad ArabBehzad DamariTehran University of Medical SciencesarticleCost effectivenessEconomic evaluationPhenylketonuriaNewborn screeningPublic aspects of medicineRA1-1270ENIranian Journal of Public Health, Vol 50, Iss 10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Cost effectiveness Economic evaluation Phenylketonuria Newborn screening Public aspects of medicine RA1-1270 |
| spellingShingle |
Cost effectiveness Economic evaluation Phenylketonuria Newborn screening Public aspects of medicine RA1-1270 Alireza Heidari Mohammad Arab Behzad Damari Lifetime Cost Effectiveness of Phenylketonuria Screening Na-tional Program in Iran |
| description |
Background: Phenylketonuria (PKU) is an autosomal recessive disorder that screening and timely control of this disorder can prevent the adverse effects. Regarding the high prevalence of PKU in Iran, the PKU screening program was started in Iran in 2006. This study was conducted to determine the cost-effectiveness of PKU screening in Iran.
Methods: An economic evaluation was performed among screened and treated individuals compared to no screening in 2013. The study population included 1356132 newborns that screened for PKU diagnosis. Lifetime costs, quality-adjusted life year (QALY) gains and incremental cost-effectiveness ratio (ICER) were calculated from the perspective of government. A discount rate of 3% was considered for both QALYs and costs. A one-way sensitivity analysis was used for assessing the robustness of the results.
Results: The discounted lifetime cost of intervention and non-intervention were $59528953.8 and $85295501.6 respectively. Therefore, the total estimated cost saving was $25766547.84. PKU screening produces an ICER of $1844420 per QALY gained.
Conclusion: Screening and early treatment for PKU is highly cost-effective. Therefore, the screening can improve quality of life of the patients and increase financial saving in health system.
|
| format |
article |
| author |
Alireza Heidari Mohammad Arab Behzad Damari |
| author_facet |
Alireza Heidari Mohammad Arab Behzad Damari |
| author_sort |
Alireza Heidari |
| title |
Lifetime Cost Effectiveness of Phenylketonuria Screening Na-tional Program in Iran |
| title_short |
Lifetime Cost Effectiveness of Phenylketonuria Screening Na-tional Program in Iran |
| title_full |
Lifetime Cost Effectiveness of Phenylketonuria Screening Na-tional Program in Iran |
| title_fullStr |
Lifetime Cost Effectiveness of Phenylketonuria Screening Na-tional Program in Iran |
| title_full_unstemmed |
Lifetime Cost Effectiveness of Phenylketonuria Screening Na-tional Program in Iran |
| title_sort |
lifetime cost effectiveness of phenylketonuria screening na-tional program in iran |
| publisher |
Tehran University of Medical Sciences |
| publishDate |
2021 |
| url |
https://doaj.org/article/d329c8e167cc4ad4ba25f7b96aa5bc6a |
| work_keys_str_mv |
AT alirezaheidari lifetimecosteffectivenessofphenylketonuriascreeningnationalprograminiran AT mohammadarab lifetimecosteffectivenessofphenylketonuriascreeningnationalprograminiran AT behzaddamari lifetimecosteffectivenessofphenylketonuriascreeningnationalprograminiran |
| _version_ |
1718376765457432576 |